A resilience-based approach to improve long-term quality of life for lymphoma survivors
Official title: Thriving Beyond Treatment: A Resilience-Based Approach to Improve Long-term Quality of Life in Post-treatment Lymphoma Survivorship.
Run by Massachusetts General Hospital · NCT07013435 · Data updated 2026-11-12
This trial tests whether a resilience-focused program helps lymphoma survivors feel a better quality of life compared with a health-education program.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 254 (estimated) |
| Sponsor | Massachusetts General Hospital Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy, radiation |
| Locations | 3 sites (Miami, Florida and 2 other locations) |
| Status | Recruiting |
| Started | October 6, 2026 |
| Main results expected | September 2029 |
| Study ends | August 2030 |
| Registry record updated | October 26, 2026 |
| Trial ID | NCT07013435 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) who are English or Spanish speaking, within 1–5 years of completing active lymphoma treatment (including maintenance), and able to participate in virtual sessions.
✕Probably not a fit
Individuals with active psychiatric, medical, or cognitive conditions, or inability to participate in virtual group sessions, may not benefit from this intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Researchers are testing a resilience and mind-body program called SMART3RP-Lymphoma to see if it improves long-term quality of life for people who have completed lymphoma treatment. The program uses techniques such as imagery, relaxation, yoga, cognitive strategies, and positive psychology, delivered in eight weekly online group sessions. Participants will complete four surveys over 12 months and provide hair cortisol samples to assess stress. The study compares SMART3RP-Lymphoma to a Health Education Program to determine its impact on quality of life and resiliency in survivors.
Why it matters
Potential benefit: If successful, participants may experience better quality of life and coping after cancer treatment.
How similar studies have gone: Past studies using resilience and mind-body approaches have shown improvements in quality of life for cancer survivors, but this specific lymphoma-focused program is a targeted, newer adaptation.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * English or Spanish speaking adults (18+ at time of enrollment) * Within 1-5 years of completing active treatment for lymphoma (includes surgery, chemotherapy, immunotherapy, radiation therapy, or other); individuals may be on maintenance treatment. Exclusion Criteria: * Active psychiatric, medical concern or cognitive comorbidity as determined by the site PI or treating clinician
Where it's running
-
Sylvester Comprehensive Cancer Center
Miami, Florida, United States Recruiting -
Mass General Hospital
Boston, Massachusetts, United States Recruiting -
Huntsman Cancer Institute
Salt Lake City, Utah, United States Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
LB-208: a new oral treatment for adults with advanced solid tumors or lymphoma
This early study tests whether LB-208, taken once daily by mouth, is safe for adults with advanced solid tumors or lymphoma who have exhausted standard treatments.
-
Tailored exercise program to improve quality of life for adults with hematologic cancers
This pilot trial tests a personalized 16-week exercise program to see if it’s feasible and helpful for adults with acute myeloid leukemia, lymphoma, or multiple myeloma after first-line treatment.
-
CD19/CD22 CAR-T consolidation after second-line therapy for high-risk aggressive B-cell lymphoma
This trial tests whether CD19/CD22 CAR-T cell therapy given after a second-line response can help people with high-risk aggressive B-cell lymphoma stay in remission.
-
Low-dose Liposomal Amphotericin B for preventing fungal infections in adults with blood cancers and prolonged neutropenia
This study tests whether giving a daily 50 mg dose of liposomal amphotericin B can help prevent invasive fungal infections in adults with blood cancers who have prolonged low white blood cell counts.
-
Genetics of Blood Cancers in the U.S. population
This study tests how genetic factors relate to blood cancers by collecting saliva DNA and online health surveys from at least 10,000 U.S. adults.
-
Glofit-GemOx Bridging to Liso-cel for Relapsed/Refractory Large B-Cell Lymphoma
This trial tests whether a bridging therapy with Glofit-GemOx followed by lisocabtagene maraleucel helps people with relapsed or refractory large B-cell lymphoma.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.